| Trial ID: | L2064 |
| Source ID: | NCT02090673
|
| Associated Drug: |
Exenatide
|
| Title: |
Post-Marketing Surveillance Study: 12 To 24 Weeks Study On The Treatment Emergent Adverse Events In Patients With Type 2 Diabetes Taking Exenatide In Korea
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes Mellitus Type 2
|
| Interventions: |
DRUG: Exenatide
|
| Outcome Measures: |
Primary: The proportion of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) in patients who are treated with Exenatide for type 2 diabetes mellitus, At 12 weeks ± 4 weeks or 24 weeks ± 4 weeks | Secondary: Change from baseline to endpoint in Hemoglobin A1c (HbA1c), Baseline (Day 1) and 12 or 24 weeks ± 4 weeks|Change from baseline to endpoint in Body weight, Baseline (Day 1) and 12 or 24 weeks ± 4 weeks|Change from baseline to endpoint in Fasting plasma glucose, Baseline (Day 1) and 12 or 24 weeks ± 4 weeks|Change from baseline to endpoint in subjective measures include improvement of main indication, Baseline (Day 1) and 12 or 24 weeks ± 4 weeks
|
| Sponsor/Collaborators: |
Sponsor: AstraZeneca
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
|
| Enrollment: |
1711
|
| Study Type: |
OBSERVATIONAL
|
| Study Designs: |
Observational Model: |Time Perspective: p
|
| Start Date: |
2009-02
|
| Completion Date: |
2014-03
|
| Results First Posted: |
|
| Last Update Posted: |
2015-08-20
|
| Locations: |
Local Institution, Seoul, 110-756, Korea, Republic of
|
| URL: |
https://clinicaltrials.gov/show/NCT02090673
|
